You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 7, July 1975 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (59)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Histocompatibility (HL-A) Antigens in Psoriasis

Leopoldo Krulig, MD; Eugene M. Farber, MD; F. Carl Grumet, MD; Rose O. Payne, PhD

Arch Dermatol. 1975;111(7):857-860.


Abstract

In 101 white psoriatic patients, two histocompatibility (HL-A) specificities were significantly altered from expected values. The levels of W16 and W17 were found to be substantially increased, suggesting that persons with these antigens are at increased risk of having psoriasis. Clinically distinct patient groups were also observed. Antigens W16 or W17 or both were more prevalent in psoriatic patients who had extensive disease involvement, and patients with W17 antigen had an earlier age of onset as compared to patients with W16 antigen. In one family in this study, a linkage between psoriasis and a specific HL-A haplotype was also observed, further supporting the concept that the HL-A system may serve as a marker for genes affecting specific disease susceptibility.



Author Affiliations

From the Department of Dermatology (Drs. Krulig and Farber), Department of Pathology (Dr. Grumet), and Department of Medicine (Dr. Payne), Stanford University Medical Center, Stanford, Calif.


Footnotes

Accepted for publication Oct 1, 1974.

Reprint requests to Department of Dermatology, Stanford University Medical Center, Stanford, CA 94305 (Dr. Farber).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cyclosporine in Psoriasis Treatment: Inhibition of Keratinocyte Cell-Cycle Progression in G1 Independent of Effects on Transforming Growth Factor {alpha}/Epidermal Growth Factor Receptor Pathways
Khandke et al.
Arch Dermatol 1991;127:1172-1179.
ABSTRACT  

The Genetics of Psoriasis: Haplotype Sharing in Siblings With the Disease
Suarez-Almazor and Russell
Arch Dermatol 1990;126:1040-1042.
ABSTRACT  

HLA Region Genes and Immune Activation in the Pathogenesis of Psoriasis
Gottlieb and Krueger
Arch Dermatol 1990;126:1083-1086.
ABSTRACT  

Mode of Inheritance in Psoriasis
Burch and Rowell
Arch Dermatol 1981;117:251-251.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1975 American Medical Association. All Rights Reserved.